Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1HTLV-I Infections 1Enteropathy-Associated T-Cell Lymphoma 1Breast Neoplasms 1

Interventions

prednylidene 1deltacortene 1Vincristine 1Specimen Handling 1Prednisone 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × HTLV-I Infections × Doxorubicin × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡